Glenmark and BeiGene ink agreement for marketing and distribution of Tislelizumab and Zanubrutinib in India

AstraZeneca sets ambition to deliver US$ 80 billion revenue by 2030

Launch of 20 new medicines expected by 2030

ASG opens its branch of super-specialty eye hospitals in Noida

ASG Group of Eye Hospitals has 165+ branches in 85+ cities across India and abroad

Dupixent late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD

Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19

SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients

Arvinas and Pfizer announce updated clinical data from Phase 1b Trial of Vepdegestrant in combination with Palbociclib

At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months

Glenmark launches next phase of ‘India First Heart First’ campaign

35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases

Takeda appoints Annapurna Das as the General Manager, India Operations

Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines

Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%

Elinzanetant significantly reduces frequency and severity of hot flashes associated with menopause

Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms